Key facts

Active substance
Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain, A/H3N2-like strain, B-like strain (Victoria lineage) and B-like strain (Yamagata lineage)
Therapeutic area
Infectious diseases
Decision number
PIP number
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
Sanofi Pasteur

Tel.  +33 437373055
E-mail: piplan@sanofi.com

Decision type
PM: decision on the application for modification of an agreed PIP


How useful was this page?

Add your rating